| Literature DB >> 33532294 |
Wojciech Krajewski1, Łukasz Nowak1, Marco Moschini2, Andrea Mari3, Ettore Di Trapani4, Evanguelos Xylinas5, Andrzej Tukiendorf6, Sławomir Poletajew7, Romuald Zdrojowy1.
Abstract
BACKGROUND: Transurethral resection of bladder tumour (TURB) is the initial and crucial step in the management of non-muscle invasive bladder cancer (NMIBC), having both diagnostic and therapeutic role. For many years, the gold standard for TURB was monopolar TURB (mTURB), however, it is associated with several complications related to its technical details. To overcome limitations of mTURB, TURB using bipolar technology (bTURB) has been developed. So far, making unequivocal statement about definitive advantage of bTURB over mTURB was difficult. The aim of this study was to systematically evaluate and compare the efficacy and safety of bTURB with mTURB.Entities:
Keywords: Bladder cancer (BC); bipolar; monopolar; transurethral resection of bladder tumour (TURB)
Year: 2021 PMID: 33532294 PMCID: PMC7844499 DOI: 10.21037/tau-20-749
Source DB: PubMed Journal: Transl Androl Urol ISSN: 2223-4683
Figure 1Flow diagram of meta-analysis.
Baseline characteristic of the included studies
| First author | Year | Country | Design | No. of patients | Matching variables* | Level of evidence** | |
|---|---|---|---|---|---|---|---|
| bTURB | mTURB | ||||||
| Bolat ( | 2018 | Turkey | RCT | 48 | 42 | 1.2, 3, 4, 5 | 2b |
| Del Rosso ( | 2013 | Italy | RCT | 67 | 65 | 1, 2, 4, 5 | 2b |
| Gramann ( | 2018 | Switzerland | RCT | 23 | 21 | 1, 2, 3, 4, 6 | 2b |
| Hashad ( | 2017 | Egypt | RCT | 100 | 100 | 1, 2, 3, 5, 6 | 2b |
| Liem ( | 2018 | The Netherlands# | Post-hoc analysis of RCT | 406 | 310 | 1, 2, 3, 4, 5, 6 | 2b |
| Mahmoud ( | 2019 | Egypt | RCT | 40 | 40 | 1, 2, 3, 4, 5, 6 | 2b |
| Murugavaithianathan ( | 2018 | India | RCT | 80 | 80 | 1, 2, 3, 4, 5, 6 | 2b |
| Teoh ( | 2016 | China | RCT | 75 | 79 | 1, 2, 3, 4, 5 | 2b |
| Venkatramani ( | 2014 | India | RCT | 72 | 75 | 1, 2, 3, 4, 5, 6 | 2b |
*: 1, age; 2, gender; 3, tumour size; 4, tumour stage; 5, tumour focality; 6, tumour localization. **, based on criteria provided by Oxford Centre for Evidence Based Medicine. #, first author’s country, study is multicenter. bTURB, bipolar transurethral resection of bladder tumour; mTURB, monopolar transurethral resection of bladder tumour; RCT, randomized controlled trial.
Eligibility criteria, exclusion criteria and tumour characteristic of particular trials
| First author, year, journal | Eligibility criteria | Exclusion criteria | Tumour size, mean (cm) | Tumour focality (n) | Final tumour stage (n) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| bTURB | mTURB | bTURB | mTURB | bTURB | mTURB | |||||
| Bolat, 2018 | Patients: who underwent TURB for overt or suspected bladder cancers on radiological imagings and/or cystoscopy; who had grade 2 or 3 coronary artery disease (CAD) according to New York Heart Association’s (NYHA) classification | Patients without coronary artery disease (CAD); acute UTI; absence of urothelial cancer on pathology report after TURB; TURB for residual tumours; re-staging or recurrent bladder tumours; patients who were not suitable for spinal anesthesia | 3 | 3.1 | 2.0±1.6 (mean number) | 1.8±1.4 (mean number) | Ta: 22; T1: 15; CIS: 1; T2:11 | Ta: 24; T1: 12; CIS: 1; T2: 6 | ||
| Del Rosso, 2013 | All patients planned for TURB with a new diagnosis of bladder tumour irrespective of size, site and multiplicity | Patients with UTI and who reported a MIBC after TURB | NR | NR | Single/multiple 56/11 | Single/multiple 54/11 | Ta: 49; T1: 18 | Ta: 47; T1: 18 | ||
| Gramann, 2018 | Tumour on the lateral bladder wall (lateral to ureteral orifice); elective TURB; operability; written informed consent | UTI; pregnancy; age <18 years or lack of legal majority; antiplatelet agents (except ASA ≤100 mg) | <1 cm: 12; >1 cm: 11 | <1 cm: 5; >1 cm: 16 | NR | NR | No tumour: 2; Ta: 16; T1: 3; T2: 2 | No tumour: 2; Ta: 13; T1:3; T2: 3 | ||
| Hashad, 2018 | Patients: presenting with bladder tumours of >3 cm in maximum diameter; receiving low-dose aspirin (81 mg/day) as antiplatelet therapy, which was not stopped before surgery | Patients with recurrent tumours and patients with CT or MRI evidence of MIBC | 3.46 | 3.5 | Single/multiple 70/30 | Single/multiple 68/32 | NR | NR | ||
| Liem, 2018 | Patients with primary NMIBC treated with mTURB or bTURB | Tumours other than NMIBC; unknown resection technique | 2.08 | 2.08 | Single/multiple 221/182 | Single/multiple 187/123 | Ta: 258; T1: 137; CIS: 11 | Ta: 153; T1: 150; CIS: 7 | ||
| Mahmoud, 2019 | Patients with newly diagnosed primary bladder tumours, with tumour size >3 cm | Patients: not suitable for spinal anaesthesia; with recurrent bladder tumours; with other urological malignancies; requiring anticoagulation; with pacemakers; with back pressure change; with urethral stricture; with active UTIs; with uncontrolled bleeding diathesis | 4.09 | 4.06 | Single/multiple 35/5 | Single/multiple 33/7 | Ta: 12; T1: 22; T2: 6 | Ta: 8; T1: 22; T2: 10 | ||
| Murugavaithianathan 2018, | Patients with bladder tumour undergoing TURB under regional anesthesia | Patients: undergoing re-TURB; requiring general anaesthesia; who refused to give informed consent | 2.7 | 2.5 | Single/multiple 65/15 | Single/multiple 70/10 | Ta: 19; T1: 35; T2: 15 | Ta: 13; T1: 44; T2: 18 | ||
| Teoh, 2016 | All patients who were diagnosed by cystoscopy to have a bladder tumour (either primary or recurrent) and who were planned for TURB | Patients who had prior TURB performed within a 6-week period | 2.34 | 2.21 | Single/multiple 45/30 | Single/multiple 45/34 | Ta: 43; T1: 13; T2: 9 | Ta: 33; T1: 22; T2: 7 | ||
| Venkatramani, 2014 | All consecutive patients undergoing TURB for suspected bladder tumours | Restaging TURB for high grade bladder cancer; refusal to participate; unfitness for spinal anesthesia | 4.38 | 4.55 | 2.51 (mean number) | 1.97 (mean number) | Ta: 21; T1:26; T2: 17; CIS: 1; Misc: 7 | Ta: 22; T1: 23; T2: 21; CIS: 0; Misc: 9 | ||
TURB, transurethral resection of bladder tumour; bTURB, bipolar transurethral resection of bladder tumour; mTURB, monopolar transurethral resection of bladder tumour; NMIBC, non-muscle invasive bladder tumour; MIBC, muscle invasive bladder tumour; UTI, urinary tract infection; CT, computed tomography; MRI, magnetic resonance imaging; NR, not reported.
Figure 2Risk of bias assessment.
Figure 3Forest plots and meta-analyses of perioperative outcomes: (A) operation time (min); (B) hospitalization time (days); (C) catheterization time (days); (D) decrease in postoperative Hb level (g/dL). bTURB, bipolar transurethral resection of bladder tumour; mTURB, monopolar transurethral resection of bladder tumour; 95% CI, 95% confidence interval; SD, standard deviation; IV, inverse variance.
Figure 4Forest plots and meta-analyses of complication rates: (A) obturator nerve reflex; (B) bladder perforation; (C) blood loss requiring transfusion. bTURB, bipolar transurethral resection of bladder tumour; mTURB, monopolar transurethral resection of bladder tumour; 95% CI, 95% confidence interval; M-H, Mantel-Haenszel method.
Figure 5Forest plot and meta-analysis of one-year recurrence rate bTURB, bipolar transurethral resection of bladder tumour; mTURB, monopolar transurethral resection of bladder tumour; 95% CI, 95% confidence interval; M-H, Mantel-Haenszel method.
Figure 6Forest plot and meta-analysis of failures in detrusor muscle detection. bTURB, bipolar transurethral resection of bladder tumour; mTURB, monopolar transurethral resection of bladder tumour; 95% CI, 95% confidence interval; M-H, Mantel-Haenszel method.